Group 1 - The medical beauty sector increased by 4.29% on November 10, with *ST Meigu leading the gains [1] - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] - The main funds in the medical beauty sector saw a net inflow of 94.61 million yuan, while retail funds experienced a net outflow of 53.71 million yuan [1] Group 2 - *ST Meigu's closing price was 4.22 yuan, with a rise of 4.98% and a trading volume of 163,200 shares, amounting to a transaction value of 68.05 million yuan [1] - Aimeike's closing price was 156.50 yuan, with a rise of 4.92% and a trading volume of 110,400 shares, amounting to a transaction value of 173.27 million yuan [1] - Huaxi Biological's closing price was 51.46 yuan, with a rise of 3.37% and a trading volume of 40,500 shares, amounting to a transaction value of 207 million yuan [1]

Investment Rating - The investment rating for the beauty and personal care industry is "Positive" (maintained) [3] Core Viewpoints - The beauty market in China showed steady performance in Q1-Q3 2025, with retail sales of cosmetics growing by 3.9% year-on-year, surpassing the overall retail sales growth of consumer goods at 3.3% [4][5] - The high-end segment is expected to outperform the mass market, with projected CAGR for high-end skincare and makeup at 9.6% and 10.8% respectively from 2023 to 2028, compared to 8.2% and 6.7% for the mass market [6] Summary by Sections Market Performance - In Q1-Q3 2025, the beauty market maintained stable demand, with monthly retail sales growth fluctuating, peaking at 8.6% in September [4][5] - The personal care segment performed well, with revenue reaching 52.3 billion yuan, a year-on-year increase of 33.7% [16] Segment Analysis - Cosmetics segment revenue was 299.9 billion yuan, with a slight increase of 0.02%, while net profit decreased by 2.5% [16] - The medical beauty segment saw revenue of 74.9 billion yuan, a decrease of 0.7%, but net profit increased by 14.5% [16] - The personal care segment's revenue growth was driven by product innovation and expansion, with notable performances from companies like RuBen and RYTHM [16] Brand Competition - The competitive landscape is stable, with domestic brands like Proya and Han Shu gaining market share, particularly in platforms like Tmall and Douyin [11][12] - The report highlights the increasing strength of domestic brands due to their brand power and local advantages [12]

Market Overview - The medical beauty sector experienced a decline of 0.93% on November 7, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - The closing prices and performance of key stocks in the medical beauty sector are as follows: - *ST Meigu: Closed at 4.02, up 1.77% with a trading volume of 143,600 shares and a turnover of 57.01 million yuan [1] - Jinbo Biological: Closed at 234.00, up 0.02% with a trading volume of 7,738.5 shares and a turnover of 1.83 billion yuan [1] - Huaxi Biological: Closed at 49.78, down 0.04% with a trading volume of 17,300 shares and a turnover of 86.15 million yuan [1] - Ai Meike: Closed at 149.16, down 1.87% with a trading volume of 30,900 shares and a turnover of 465 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 46.6453 million yuan from main funds, while retail investors contributed a net inflow of 34.3979 million yuan [1] - The capital flow for key stocks is as follows: - *ST Meigu: Net outflow of 2.6832 million yuan, down 4.71% [2] - Huaxi Biological: Net outflow of 3.3342 million yuan, down 3.87% [2] - Ai Meike: Net outflow of 40.6279 million yuan, down 8.74% [2]

Market Overview - On November 7, the three major A-share indices collectively declined, with the Shanghai Composite Index down 0.25%, the Shenzhen Component Index down 0.36%, and the ChiNext Index down 0.51% [1] - The total trading volume in the Shanghai and Shenzhen markets was approximately 19990.53 billion yuan, a decrease of about 561.94 billion yuan compared to the previous trading day [1] - Out of 2101 stocks, 3162 stocks declined, with 63 hitting the daily limit up and 8 hitting the daily limit down [1] Regional Performance - The Shanxi sector showed signs of weakness on November 7, with a fluctuation of 0.86% and a trading volume of 129.57 billion yuan, comprising 12 stocks that rose, 3 that remained flat, and 26 that fell [1] - Among Shanxi stocks, Lu Hua Technology hit the daily limit up around 9:44 AM, while two other stocks rose over 2% [1] - Notable gainers included Huayang Co., which rose by 4.69%, and Guangyuyuan, which increased by 3.54% [1] - Other stocks with slight increases included Jinkong Coal, Pilin Bio, Kexin Development, Yabao Pharmaceutical, Tongde Chemical, Yongdong Co., Tongbao Energy, Shanmei International, and Jinbo Bio [1] Decliners in Shanxi Sector - The leading decliner was Shanxi Expressway, which fell by 6.57%, while other Shanxi stocks experienced declines ranging from 0.13% to 4.33% [1] - Stocks such as Lanyuan Science and Technology, Daqin Railway, and Blue Flame Holdings remained flat [1]

Core Viewpoint - Shanxi, known for its historical sites and coal resources, is rapidly developing its biopharmaceutical industry, with Jinbo Biotech, founded by Yang Xia, emerging as a key player [1][4]. Company Overview - Yang Xia, after graduating from Shanxi Medical University, identified a gap in the market for human collagen extraction, which was dominated by foreign technology. She founded Jinbo Biotech in 2008 to tackle this challenge [4][6]. - The company successfully developed the world's first recombinant type III humanized collagen product in 2014, breaking the foreign monopoly on this technology [4][6]. Product Innovation - The recombinant type III humanized collagen has a unique 164.88° triple helix structure, enhancing cell adhesion and has applications in advanced implant materials, wound care, and anti-aging cosmetics [6][8]. - Jinbo Biotech's industry standards have been incorporated into the national medical device regulatory system, and it is the only company in China with class III medical device certification for recombinant humanized collagen [6][8]. Technological Advancements - The company is developing an injectable form of recombinant type III humanized collagen gel, which utilizes self-assembling properties to create a honeycomb structure, addressing safety concerns related to residual cross-linking agents [8][10]. - Yang Xia emphasizes that high-end products should be priced based on technology rather than cost, asserting that Jinbo holds pricing power due to its unique technology and extensive R&D investment [8][10]. Market Position and Future Outlook - Jinbo Biotech is positioned as a leader in the emerging recombinant collagen market, gaining recognition as a "star stock" after listing on the Beijing Stock Exchange [6][12]. - Yang Xia acknowledges the volatility of market valuations, stating that a company's performance directly impacts its market value, highlighting the importance of sustained innovation and execution [12].

Core Insights - The A-share market showed a strong upward trend, with the Shanghai Composite Index rising by 0.97% to 4007.76 points, and the Shenzhen Component Index increasing by 1.73% [2][8] - The total trading volume in the A-share market reached approximately 2.05 trillion RMB, with over 2800 stocks experiencing gains [2][8] - The leading sectors included non-ferrous metals, electronics, and telecommunications, while the media sector lagged behind [2][8] - In the Hong Kong market, the Hang Seng Index closed up by 2.12%, and the Hang Seng Tech Index rose by 2.74% [2][8] - In contrast, all three major US stock indices closed lower, with the Dow Jones down by 0.84%, the S&P 500 down by 1.12%, and the Nasdaq down by 1.9% [2][8] Important News - President Xi Jinping emphasized the high-standard construction of the Hainan Free Trade Port, marking it as a significant step towards expanding high-level opening-up and promoting an open world economy [3][9] - The strategic goal of the Hainan Free Trade Port is to become a key gateway for China's new era of opening-up, focusing on high-quality development and integrating with major economic regions [3][9] Fund Allocation Insights - As of Q3 2025, the total net value of all funds in the market reached 35.16 trillion RMB, with equity and mixed funds accounting for 24.33% of the total [10] - The overall fund position increased to 80.03%, with equity mixed funds at 74.77% and ordinary equity funds at 82.14% [10] - The performance of various fund types varied significantly, with equity funds achieving a return of 24.14% and mixed funds at 20.87% for the quarter [11] Beauty and Personal Care Sector - In Q3 2025, the fund allocation ratio for the beauty and personal care sector decreased to 0.20%, indicating a low allocation level [14][15] - The medical beauty sub-sector remains in an overweight position, while personal care and cosmetics are underweighted [15][16] - The top three stocks in the beauty and personal care sector by fund allocation are Jinbo Biological, Aimeike, and Baiya Shares, although their allocation ratios have declined [16] Precision Reducer Industry - The precision reducer is a core component in the transmission field, crucial for humanoid robots, with significant market potential expected by 2030 [18][21] - The market for precision reducers is projected to grow substantially, with the domestic market for harmonic reducers expected to reach 24.9 billion RMB in 2023, growing at a CAGR of 16.54% from 2019 to 2023 [20] - The domestic production of precision reducers is increasing, with local manufacturers gradually closing the gap with international standards, indicating a strong trend towards domestic substitution [22]

Core Viewpoint - The article highlights the rapid rise of Jinbo Biotechnology, a company founded by Yang Xia, in the biopharmaceutical industry in Shanxi, showcasing its innovative achievements in recombinant collagen products and its significant market presence after listing on the Beijing Stock Exchange [1][8]. Company Overview - Jinbo Biotechnology was established in 2008 by Yang Xia, who aimed to develop synthetic collagen to reduce the high costs and improve the success rates of organ transplants [3][4]. - The company successfully developed the world's first recombinant type III humanized collagen gel without cross-linking agents, marking a significant technological breakthrough [11][19]. Financial Performance - From 2021 to 2024, Jinbo Biotechnology's revenue increased from 233 million yuan to 1.443 billion yuan, and after its listing in July 2023, the company's market capitalization approached 30 billion yuan, making it a leading stock on the Beijing Stock Exchange [8][19]. Product Development - Jinbo's recombinant type III humanized collagen has identical amino acid sequences to natural type III collagen and is used in various applications, including advanced implant materials and skincare products [6][11]. - The company has developed a range of products, including the "Wei Yi Mei" series, which became the first injectable-grade human collagen product to be commercialized globally [6][8]. Technological Innovation - Jinbo Biotechnology emphasizes original innovation, having established a fully integrated production facility for humanized collagen products, utilizing advanced technologies such as industrial IoT and AI [11][19]. - The company has participated in setting industry standards for recombinant collagen, further solidifying its leadership position in the global market [13][19]. Strategic Partnerships - In June 2023, Jinbo Biotechnology attracted significant investment from strategic partners, including Nongfu Spring and Wantai BioPharma, indicating strong confidence in the company's growth prospects [18]. - The collaboration aims to enhance the company's capabilities and expand its market reach, particularly in the health and beauty sectors [18][19]. Future Outlook - Jinbo Biotechnology plans to continue advancing its research in recombinant collagen technology and expand its product offerings in the healthcare and life care sectors, aiming to become a leading innovative biopharmaceutical company [19][21].

Core Insights - As of November 6, the total margin financing and securities lending balance on the Beijing Stock Exchange (BSE) is 7.958 billion yuan, a decrease of 16.7738 million yuan from the previous trading day [1] - The stocks with the highest margin financing balances include Jinbo Biological, Shuguang Digital Innovation, and Betterray, with balances of 406 million yuan, 332 million yuan, and 264 million yuan respectively [1] - A total of 131 stocks on the BSE received net margin purchases, with 36 stocks having net purchases exceeding 1 million yuan, led by Kaifa Technology with a net purchase of 16.6739 million yuan [1][2] Margin Financing Overview - The margin financing balance on November 6 is 7.957 billion yuan, down by 16.7451 million yuan, marking a decrease for three consecutive trading days [1] - The securities lending balance is 442,700 yuan, a decrease of 28,700 yuan from the previous trading day [1] Sector Performance - The sectors with the most stocks receiving net margin purchases over 1 million yuan are electric power equipment, machinery, and pharmaceutical biology, with 9, 6, and 5 stocks respectively [2] - On November 6, the average decline for stocks with net margin purchases exceeding 1 million yuan was 1.90%, with Lingge Technology, Tianming Technology, and Audiwei showing increases of 2.87%, 0.88%, and 0.70% respectively [2] Trading Activity - The weighted average turnover rate for stocks with net margin purchases over 1 million yuan on November 6 was 5.92%, with the highest turnover rates seen in Caneng Electric, Kerun Zhikong, and Deer Chemical at 49.67%, 21.24%, and 20.75% respectively [2] - The average daily turnover rate for BSE stocks on the same day was 3.71% [2] Notable Stocks - The stocks with the largest increases in margin financing on November 6 include Kaifa Technology (increase of 16.6739 million yuan), Tianming Technology (increase of 7.9101 million yuan), and Qiaoguan Cable (increase of 6.7871 million yuan) [2][3] - Stocks with the largest net margin sales include Betterray, Shuguang Digital Innovation, and Danna Biological, with net sales of 20.1779 million yuan, 13.0228 million yuan, and 11.6394 million yuan respectively [1][2]

Quantitative Models and Construction Model Name: Market Size Factor Model - **Construction Idea**: The model analyzes the performance of market size factors under different monetary policy cycles, focusing on the advantage of small-cap stocks during a loose monetary environment [9][11][68] - **Construction Process**: 1. Define monetary policy cycles based on the trends of 1-year and 10-year government bond yields. If both yields decline simultaneously, it indicates a loose monetary policy period; if both rise, it indicates a tight monetary policy period. Contradictory signals are ignored, and the previous period's judgment is retained [9]. 2. Divide market size factors into deciles and calculate the long-short net value performance under loose and tight monetary cycles [9][15]. 3. Empirical results show that during loose monetary cycles, the net value of small-cap portfolios outperforms large-cap portfolios, while the opposite is true during tight monetary cycles [9][15]. - **Evaluation**: The model effectively captures the relationship between monetary policy cycles and market size factor performance, highlighting the advantage of small-cap stocks in a loose monetary environment [9][11][68]. --- Quantitative Factors and Construction Factor Name: "Specialized, Refined, Distinctive, and Innovative" (专精特新) Factor - **Construction Idea**: The factor identifies small and medium-sized enterprises with significant competitive advantages in niche markets, characterized by high innovation and quality [12][16][69]. - **Construction Process**: 1. Select companies listed on the Beijing Stock Exchange (BSE) with high proportions of high-tech enterprises and strategic emerging industries [12][16]. 2. Focus on companies categorized as "national-level specialized, refined, distinctive, and innovative small giants" [12][16]. 3. Analyze industry distribution, emphasizing sectors like advanced manufacturing, green energy, and digital economy [12][16][69]. - **Evaluation**: The factor aligns closely with national policies supporting high-quality SMEs, reflecting strong growth potential and policy-driven advantages [12][16][69]. --- Backtesting Results of Models and Factors Market Size Factor Model - **Annualized Return**: Small-cap portfolios outperform large-cap portfolios during loose monetary cycles [9][15]. - **Performance Trend**: Net value of small-cap portfolios shows a steady upward trend under loose monetary conditions [9][15]. "Specialized, Refined, Distinctive, and Innovative" Factor - **Proportion in BSE 50 Index**: Approximately 66% of the BSE 50 Index constituents are categorized as "specialized, refined, distinctive, and innovative" enterprises, significantly higher than other indices [32][69]. - **Sector Concentration**: The factor is highly concentrated in industries like machinery, chemicals, and computing, accounting for nearly 60% of the index weight [29][30][69]. --- Performance Metrics of Related Funds Fund Name: 中加专精特新量化选股A - **Annualized Return (2025)**: 75.56% [56][57]. - **Maximum Drawdown (2025)**: 12.77%, lower than the average of similar funds (15.38%) [56][57]. - **Recovery Days**: 18 days [56][57]. Fund Name: 中加中证A500指数增强A - **Annualized Return (2025)**: 33.50%, higher than the average of similar funds (23.88%) [64][67]. - **Maximum Drawdown**: 11.45%, better than the benchmark index (11.89%) [67]. - **Performance Ranking**: Ranked 14th among 68 similar funds [64][67]. Fund Name: 中加中证500指数增强A - **Annualized Return (2024-2025)**: 33.84%, exceeding the benchmark index by 5.70% [63]. - **Maximum Drawdown**: 11.60%, lower than the benchmark index (16.48%) [63]. - **Sharpe Ratio**: 1.64, higher than the benchmark index (1.30) [63]. - **Calmar Ratio**: 2.94, outperforming the benchmark index (2.00) [63].

Core Insights - The average stock price of A-shares is 13.99 yuan, with 155 stocks priced over 100 yuan, an increase of 4 from the previous trading day [1] - The Shanghai Composite Index closed at 4007.76 points, up 0.97%, while stocks over 100 yuan had an average increase of 2.34%, outperforming the index by 1.37 percentage points [1] - The top-performing stocks over 100 yuan include Cambrian Technology, Kweichow Moutai, and Yuanjie Technology, with closing prices of 1480.00 yuan, 1435.13 yuan, and 616.53 yuan respectively [1] Market Performance - The average increase of stocks priced over 100 yuan in the last month was 0.44%, while the Shanghai Composite Index rose by 3.22% [2] - Notable gainers in the past month include Yunhan Chip City, Xiangnan Chip Creation, and Ding Tai High-Tech, with increases of 82.01%, 76.54%, and 65.38% respectively [2] - Year-to-date, the average increase of stocks over 100 yuan is 109.55%, outperforming the Shanghai Composite Index's 89.98% [2] Industry Distribution - The majority of stocks over 100 yuan are concentrated in the electronics, computer, and machinery sectors, with 58 stocks from the electronics sector, accounting for 37.42% of the total [2] - The stock distribution by board shows that there are 31 stocks from the main board, 50 from the ChiNext, 4 from the Beijing Stock Exchange, and 70 from the Sci-Tech Innovation Board, with the latter making up 45.16% of the total [2] Institutional Ratings - Five stocks priced over 100 yuan received "buy" ratings from institutions, including Zhaoyi Innovation, Wancheng Group, and Tuojing Technology, with Tuojing Technology being newly covered by institutions [2] - Among the rated stocks, two have target prices indicating an upside potential exceeding 10%, with Jinbo Biological having the highest potential of 48.88% [3]